RecruitingPhase 3NCT04528082
Immune
Behcet Disease
Also known as Behcet syndrome, Behcet's disease, triple symptom complex, silk road disease
Behcet Disease is a systemic vasculitis of unknown etiology involving vessels of all sizes and characterized by the pathognomonic triad of recurrent oral aphthous ulcers, genital ulcers, and ocular inflammation, with additional potential in
ORPHA:117 ↗Prevalence 1-10 in 100,000 in Western countries; up to 420 in 100,000 in TurkeyOnset Young adulthood (20s-30s), rarely pediatricVariable vessel vasculitis / autoinflammatory syndrome
24
studies recruiting now
as of 7 Sept 2026
135
studies registered in total
as of 7 Sept 2026
25
countries with a recruiting site
as of 7 Sept 2026
14 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT06371417
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
RecruitingNot applicableNCT07702123
Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet Disease
RecruitingNot applicableNCT07702149
Diet Restiction in Subjects With Behcet Disease and Complaint of Tinnitus
RecruitingNot applicableNCT07662603
Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle Trianing
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 24 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Behcet Disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: International Behcet Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Behcet Disease
Behcet Disease is a systemic vasculitis of unknown etiology involving vessels of all sizes and characterized by the pathognomonic triad of recurrent oral aphthous ulcers, genital ulcers, and ocular inflammation, with additional potential involvement of the skin, joints, gastrointestinal tract, and central nervous system. Strong HLA-B51 association suggests an autoinflammatory mechanism, though the precise immunopathogenesis remains incompletely understood. The disease follows a relapsing-remitting course and can cause irreversible organ damage, particularly vision loss from uveitis and neurological deficits from neuro-Behcet.
Common clinical features
Recurrent painful oral aphthous ulcers (≥3 episodes per year)Recurrent genital ulcers with scarringUveitis (anterior, posterior, or panuveitis)Pathergy reaction (skin hyper-reactivity to trauma)Erythema nodosum and pseudofolliculitisThrombophlebitis and deep vein thrombosisNeuro-Behcet (headache, brainstem lesions, cognitive change)
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
2 approved treatments and 16 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Ezogabine (Potiga)Approved: Apremilast (Apremilast accord)
Phase 3Gevokizumab
Phase 3Secukinumab (Cosentyx)
Phase 3Infliximab (Flixabi)
Phase 3Mufemilast
Phase 2Aldesleukin (Proleukin)
Phase 2Canakinumab (Ilaris)
Phase 2Upadacitinib (Upadacitinib component of abbv-599)
Phase 2Ustekinumab (Stelara)
+ 8 more in development
Before you apply
Things trial teams commonly ask about for Behcet Disease. Not eligibility rules; those are set by each study.
- International Study Group diagnostic criteria fulfillment is typically required; compile documentation of ulcer frequency, eye exam reports, and pathergy test results
- Uveitis trials often stratify by ocular involvement severity and prior biologic use (anti-TNF, interferon); have complete ophthalmology records and visual acuity measurements available
- Active major vessel disease (arterial aneurysm, venous thrombosis) may require separate anticoagulation management and can affect trial eligibility — disclose vascular history fully
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).